Search results for "Follow-up studies"

showing 10 items of 2210 documents

Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I

2018

The quantification of enzyme activity in the patient treated with enzyme replacement therapy (ERT) has been suggested as a tool for dosage individualization, so we conducted a study to evaluate the relationship between glucocerebrosidase activity and clinical response in patients with Gaucher disease type I (GD1) to ERT. The study included patients diagnosed with GD1, who were being treated with ERT, and healthy individuals. Markers based on glucocerebrosidase activity measurement in patients' leucocytes were studied: enzyme activity at 15 min. post-infusion (Act75 ) reflects the amount of enzyme that is distributed in the body post-ERT infusion, and accumulated glucocerebrosidase activity …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyDiseaseToxicologySeverity of Illness IndexGastroenterology03 medical and health sciencesGlucocerebrosidase activity0302 clinical medicineStatistical significanceInternal medicineLeukocytesHumansMedicineEnzyme Replacement TherapyIn patientProspective Studies030212 general & internal medicineInverse correlationAgedEnzyme AssaysPharmacologyGaucher DiseaseDose-Response Relationship Drugbiologybusiness.industryArea under the curvenutritional and metabolic diseasesGeneral MedicineEnzyme replacement therapyMiddle AgedEnzyme assayTreatment Outcome030220 oncology & carcinogenesisbiology.proteinGlucosylceramidaseFemalebusinessBiomarkersFollow-Up StudiesBasic & Clinical Pharmacology & Toxicology
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

A Prospective Randomized Study of Corticosteroids as Adjuvant Drugs to Opioids in Advanced Cancer Patients

2007

This randomized controlled study evaluated the role of corticosteroids as adjuvants to opioid therapy in 76 advanced cancer patients with pain who requiring strong opioids. Patients were divided in 2 groups. Group O received conventional opioid treatment. Group OS received dexamethasone (8 mg orally) along with conventional treatment. Pain and symptom intensity, sense of well-being, and opioid escalation index and distress score were recorded at weekly intervals until death. No differences in pain intensity, opioid consumption, and opioid escalation index were found in 66 patients who survived 33 to 37 days. Corticosteroids did not provide significant additional analgesia to opioids, but p…

AdultMalecorticosteroidmedicine.medical_treatmentAnti-Inflammatory Agentslaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trial030502 gerontologylawNeoplasmsmedicineHumansProspective Studiesopioids in advanced cancer patientsprospective randomized studyProspective cohort studyDexamethasoneAgedPain MeasurementAged 80 and overAnalysis of VarianceChemotherapyadjuvant drugDose-Response Relationship Drugbusiness.industryPalliative CareGeneral MedicineMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidChemotherapy Adjuvant030220 oncology & carcinogenesisAnesthesiaDrug Therapy CombinationFemale0305 other medical scienceCancer painbusinessAdjuvantFollow-Up Studiesmedicine.drugAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease

2019

Abstract Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibitio…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismGraves' diseaseClinical BiochemistryThyrotropinContext (language use)dilution analysisBiochemistryGastroenterologyThyrotropin receptorThyroid binding inhibitory immunoglobulinsYoung AdultMethimazoleEndocrinologyTSH-R stimulating antibodiesInternal medicineGraves hyperthyroidismmedicineHumansprospective trialProspective StudiesAutoantibodiesClinical Research Articlebiologybusiness.industryBiochemistry (medical)Receptors ThyrotropinMiddle AgedPrognosismedicine.diseaseeye diseasesGraves DiseaseTSH-R blocking antibodiesTiterEndocrinologyProspective trialbiology.proteinFemaleAntibodybusinessBiomarkersAcademicSubjects/MED00250Follow-Up Studiesmedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Descriptive retrospective study analyzing relevant factors related to dental implant failure

2019

Background The objective of this retrospective descriptive study was to analyze the characteristics of incident reports provided by dentists while using a specific brand of dental implants. Material and Methods The study was carried out in collaboration with Oxtein Iberia S.L.®, with the company providing access to the incident database in order to evaluate the characteristics of incidents from January 2014 to December 2017 (a total of 917 over four years). The data sheet recorded different variables during each of the stages of implant treatment, from initial implant placement to subsequent prosthetic rehabilitation. These variables included age, sex, systemic pathologies, smoking habits, …

AdultMalegovernment.form_of_governmentmedicine.medical_treatmentDentistryProsthesisOsseointegration03 medical and health sciences0302 clinical medicineOsseointegrationmedicineHumansDental Restoration FailureDental implantGeneral DentistryAgedRetrospective StudiesDental ImplantsTitaniumOral Medicine and Pathologybusiness.industryResearchDental Implantation EndosseousDental prosthesisImplant failureRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Treatment OutcomeDental Prosthesis DesignOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASgovernmentBruxismFemaleSurgeryDental Prosthesis Implant-SupportedImplantbusinessFollow-Up StudiesIncident reportMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Gray matter integrity predicts white matter network reorganization in multiple sclerosis

2019

Abstract Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease leading to gray matter atrophy and brain network reconfiguration as a response to increasing tissue damage. We evaluated whether white matter network reconfiguration appears subsequently to gray matter damage, or whether the gray matter degenerates following alterations in white matter networks. MRI data from 83 patients with clinically isolated syndrome and early relapsing–remitting MS were acquired at two time points with a follow‐up after 1 year. White matter network integrity was assessed based on probabilistic tractography performed on diffusion‐weighted data using graph theoretical analyses. We ev…

AdultMalegraph theory610 MedizinneuropsychologytractographyBiologyNeuropsychological Testsmultiple sclerosisGray (unit)050105 experimental psychologyWhite matter03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-Remittingatrophy610 Medical sciencesmedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingstructural connectivityGray Matternetwork analysisResearch ArticlesTemporal cortexCerebral CortexClinically isolated syndromeRadiological and Ultrasound TechnologyMultiple sclerosisPutamen05 social sciencesMiddle Agedmedicine.diseaseWhite Mattermedicine.anatomical_structureDiffusion Tensor ImagingNeurologyDisease ProgressionFemaleNeurology (clinical)AnatomyNerve NetNeuroscience030217 neurology & neurosurgeryTractographyResearch ArticleFollow-Up StudiesHuman Brain Mapping
researchProduct

Clinical and imaging outcome of osteochondral lesions of the talus treated using autologous matrix-induced chondrogenesis technique with a biomimetic…

2017

Abstract Background The purpose of our study was to assess the clinical and imaging outcome of autologous matrix-induced chondrogenesis (AMIC) technique consisting of microfractures followed by the filling of osteochondral lesions of the talus (OLTs) with a cell-free biphasic collagen-hydroxyapatite osteochondral scaffold (MaioRegen). Methods Sixteen patients (eight males, age: 42.6 ± 18.4, range 14–74) with OLT repaired using AMIC technique, with implantation of MaioRegen, were clinically evaluated through the American Orthopedic Foot and Ankle Society Score (AOFAS) and a 10-point Visual Analogue Scale (VAS) pain score after a mean follow-up of 30 ± 16.9 months. The MRI examinations were p…

AdultMalelcsh:Diseases of the musculoskeletal systemAdolescentFractures StressTissue ScaffoldsMiddle AgedTransplantation AutologousTalusScaffoldYoung AdultTreatment OutcomeCartilageMagnetic resonance imagingBiomimetic MaterialsHumansFemalelcsh:RC925-935ChondrogenesisOsteochondral lesionResearch ArticleAgedFollow-Up StudiesRetrospective StudiesBMC Musculoskeletal Disorders
researchProduct

[Arterial hypertension and prediabetes].

2016

Abstract Background and objectives The aim of this study was to assess the factors related to new diabetes in hypertensive. Patients and methods This prospective follow-up study involved 2588 non-diabetic, hypertensive patients. The total follow-up was 15,053 patient-years with a median of 3.4 years (interquartile interval 1.4–6.8). Results During the follow-up, 333 (13%) patients had new diabetes, with a conversion rate of 2.21 (95% confidence interval [CI], 1.98–2.46) 100/patients/year. In a Cox proportional hazard model including baseline characteristics and modifications during the follow-up the three components of metabolic syndrome (excluding blood pressure and glucose values) HR 1.69…

AdultMalemedicine.medical_specialty030204 cardiovascular system & hematologyPrediabetic State03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicinePrediabetesProspective StudiesFamily historyAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence intervalPrimary PreventionEndocrinologyBlood pressureDiabetes Mellitus Type 2HypertensionFemaleMetabolic syndromebusinessFollow-Up StudiesMedicina clinica
researchProduct

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct